Enucleation with or without adjuvant therapy versus marsupialization with or without secondary enucleation in the treatment of keratocystic odontogenic tumors: A systematic review and meta-analysis

2016 ◽  
Vol 44 (9) ◽  
pp. 1395-1403 ◽  
Author(s):  
Essam Ahmed Al-Moraissi ◽  
M. Anthony Pogrel ◽  
Edward Ellis
2014 ◽  
Vol 42 (7) ◽  
pp. e364-e371 ◽  
Author(s):  
Georgios N. Antonoglou ◽  
George K. Sándor ◽  
Vasiliki P. Koidou ◽  
Spyridon N. Papageorgiou

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Dominic O’Connor ◽  
Malcolm Brown ◽  
Martin Eatock ◽  
Richard C. Turkington ◽  
Gillian Prue

Abstract Background Surgical resection remains the only curative treatment for pancreatic cancer and is associated with significant post-operative morbidity and mortality. Patients eligible for surgery, increasingly receive neo-adjuvant therapy before surgery or adjuvant therapy afterward, inherently exposing them to toxicity. As such, optimizing physical function through exercise during treatment remains imperative to optimize quality of life either before surgery or during rehabilitation. However, current exercise efficacy and prescription in pancreatic cancer is unknown. Therefore, this study aims to summarise the published literature on exercise studies conducted in patients with pancreatic cancer undergoing treatment with a focus on determining the current prescription and progression patterns being used in this population. Methods A systematic review of four databases identified studies evaluating the effects of exercise on aerobic fitness, muscle strength, physical function, body composition, fatigue and quality of life in participants with pancreatic cancer undergoing treatment, published up to 24 July 2020. Two reviewers independently reviewed and appraised the methodological quality of each study. Results Twelve studies with a total of 300 participants were included. Heterogeneity of the literature prevented meta-analysis. Exercise was associated with improvements in outcomes; however, study quality was variable with the majority of studies receiving a weak rating. Conclusions High quality evidence regarding the efficacy and prescription of exercise in pancreatic cancer is lacking. Well-designed trials, which have received feedback and input from key stakeholders prior to implementation, are required to examine the impact of exercise in pancreatic cancer on key cancer related health outcomes.


2003 ◽  
Vol 13 (4) ◽  
pp. 395-404 ◽  
Author(s):  
B. Winter-Roach ◽  
L. Hooper ◽  
H. Kitchener

A systematic review and meta analysis has been undertaken in order to evaluate the effectiveness of adjuvant therapy following surgery for early ovarian cancer. Trials reported since 1990 have been of a higher quality enabling a meta analysis of adjuvant chemotherapy vs adjuvant radiotherapy and a meta analysis of adjuvant chemotherapy vs observation. There was no significant difference between radiotherapy and chemotherapy, though these comprised studies which demonstrated considerable heterogeneity. Chemotherapy did confer significant benefit over observation in terms of both overall and disease free survival. Except for women in whom adequate surgical staging has revealed well differentiated disease confined to one or both ovaries with intact capsule, platinum chemotherapy should be offered to reduce risk of recurrence.


2015 ◽  
Vol 73 (2) ◽  
pp. 264-271 ◽  
Author(s):  
Lihi Atzmony ◽  
Emmilia Hodak ◽  
Yael A. Leshem ◽  
Omer Rosenbaum ◽  
Michael Gdalevich ◽  
...  

2020 ◽  
Vol 9 (2) ◽  
pp. 305-319
Author(s):  
Tamata T. S. Sousa ◽  
Silvana A. Schellini ◽  
Roberta L. F. S. Meneghim ◽  
Antonio J. M. Cataneo

2020 ◽  
Vol 26 (11) ◽  
pp. 2664-2672 ◽  
Author(s):  
Farshad Nassiri ◽  
Shervin Taslimi ◽  
Justin Z. Wang ◽  
Jetan H. Badhiwala ◽  
Tatyana Dalcourt ◽  
...  

2020 ◽  
Vol 27 (1) ◽  
Author(s):  
M. Kish ◽  
K. Chan ◽  
K. Perry ◽  
Y.J. Ko

Background Recent randomized controlled trials (rcts) have contributed high-quality data about adjuvant therapy in curatively resected biliary tract cancer (btc); however, a standard approach to treating those patients still has not been developed.Methods We conducted a systematic review of published studies and abstracts up to and including June 2018, choosing rcts involving patients with btc receiving adjuvant chemotherapy after complete surgical resection. Network meta-analysis methods were used for indirect comparisons of overall survival (os) and relapse-free survival (rfs) for various adjuvant therapies.Results Five rcts were included in qualitative synthesis, and three rcts (bilcap, prodige 12–accord 18, and bcat) had data sufficient for inclusion in the meta-analysis. Results from the indirect comparison demonstrated no significant improvement in os for capecitabine compared with gemcitabine or with gemcitabine–oxaliplatin (gemox), the hazard ratios (hrs) being 0.82 [95% confidence interval (ci): 0.53 to 1.27] and 0.86 (95% ci: 0.56 to 1.34) respectively. Similarly, no significant improvement in rfs was observed for capecitabine compared with gemcitabine or gemox.Conclusions Although in the present analysis, we found no statistically significant improvements in os or rfs for capecitabine compared with gemox or gemcitabine, capecitabine can—until further prospective trials are completed— be considered the standard of care in the adjuvant setting based on a single randomized phase iii study.


2020 ◽  
Vol 34 (5) ◽  
pp. 956-966
Author(s):  
C. Longo ◽  
R. Pampena ◽  
A. Lallas ◽  
A. Kyrgidis ◽  
A. Stratigos ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document